Healthcare / Medical DistributionBVB
$0.80
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $19.0M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$75M
P/E
10.0x
↓EV/EBITDA
1.0x
↓ROE
10.1%
↑Gross Margin
8.0%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.3%
FCF CAGR
—
FCF margin
2.0%
FCF / Net income
1.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $759.8M · net income $8.0M · FCF $15.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $759.8M | $759.8M | $743.8M | $593.4M | $535.9M |
| Net Income | $8.0M | $8.0M | $7.0M | $7.2M | $5.8M |
| EBITDA | $18.7M | $18.7M | $16.8M | $14.1M | $11.2M |
| EPS | — | — | — | 0.08 | 0.06 |
| Gross Margin | 8.0% | 8.0% | 7.8% | 7.7% | 8.3% |
| Operating Margin | 2.0% | 2.0% | 1.8% | 1.3% | 1.3% |
| Net Margin | 1.1% | 1.1% | 0.9% | 1.2% | 1.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 |
| Current Ratio | 1.11 | 1.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.5M | $15.5M | $19.0M | $23.2M | $-2.0M |
| Returns | |||||
| ROE | 10.1% | 10.1% | 9.4% | 10.2% | 8.5% |
| Valuation | |||||
| P/E | 10.00 | 10.00 | — | 9.22 | 10.16 |
| EV/EBITDA | 0.95 | 0.95 | 0.81 | 2.41 | 3.75 |
| P/B | 0.94 | 0.94 | 0.82 | 0.94 | 0.86 |
| Growth & Yield | |||||
| Revenue Growth | 2.1% | 2.1% | 25.4% | 10.7% | — |
| EPS Growth | — | — | — | 24.0% | — |
| Dividend Yield | 6.3% | 6.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+20.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.